Pulmatrix secured $1 million via a private Placement of Series B convertible preferred stock, a sum equal to about 17 % of its $6 million market capitalisation. The injection shored up liquidity, giving the firm the financial cushion needed to pursue its pending Merger with Eos Senolytix and sustain operations through the end of the year.

Key Highlights

  • Price $1.60 · Mkt cap $6 million · $1.0 million raised · Next catalyst: third‑quarter 2026 merger
  • EPS $‑0.42 for Q2 2025 reported, underscoring ongoing losses
  • Cash and cash equivalents $2.2 million, with $0.7 million restricted cash pending merger

Pulmatrix, Inc. (NASDAQ: PULM) is a micro‑cap biopharmaceutical firm with a Market Capitalisation of $6 million, 3,652,285 shares outstanding and $2.2 million in cash and cash equivalents. The company focuses on inhaled therapeutics built on its iSPERSE™ platform and is managing a strategic consolidation with Eos Senolytix. On August 13, 2026, Pulmatrix announced that it raised $1 million through a private placement of newly designated Series B Convertible Preferred Stock, a transaction that directly supports its merger timetable and operational runway.

$1 Million Convertible Preferred Offering

The financing round added $1 million in gross proceeds, representing roughly 17 % of Pulmatrix’s $6 million market capitalisation. The company’s quarterly Earnings Per Share for the period ending June 30, 2025 stood at $‑0.42, highlighting persistent net losses that the new funding aims to alleviate. By converting the Preferred Shares into common Equity under predefined terms, the company can potentially improve its Balance Sheet without diluting existing shareholders immediately.

This injection also adds a layer of financial resilience as the firm awaits the merger’s closing, which remains contingent on customary conditions. The capital boost thus narrows the gap between existing cash reserves and the cash needed to sustain operations through the anticipated transaction.

Merger Funding Mechanics

The $1 million proceeds sit alongside $2.2 million in cash and cash equivalents and $0.7 million of restricted cash that will become unrestricted once the merger finalises. Total current Assets fell to $3.239 million from $4.129 million a year earlier, reflecting a strategic contraction of the balance sheet as the company trims non‑essential expenditures. Meanwhile, Research and Development outlays remained modest, under $0.1 million.

The reduction in operating expenses, coupled with the new preferred‑stock proceeds, positions Pulmatrix with sufficient Liquidity to fund its obligations at least until the projected third‑quarter 2026 merger closure. The modest debt‑to‑equity ratio of zero underscores the firm’s reliance on Equity Financing rather than borrowing, a stance that keeps covenant risk low but places emphasis on equity‑based capital sources. Consequently, the company’s financing structure now leans heavily on equity infusion, which may affect future dilution calculations for shareholders.

Market Reaction and Technical Outlook

Shares traded at $1.60, down 29.2 % year‑to‑date and 1.2 % over the past month, hovering below the 20‑day ($1.67), 50‑day ($1.60) and 200‑day ($2.37) moving averages, signaling a bearish trend. The 14‑day RSI of 35.5 and MACD at -0.01 beneath its 0.01 signal line indicate weak momentum and potential oversold conditions. Nearest support levels sit at $1.57 and $1.40, while resistance sits at $1.89 and $2.05.

Peer performance on the same day showed CURX down 2.0 %, RVPH up 3.6 % and ENVB down 1.9 %, providing a mixed backdrop for the sector. The technical positioning suggests the stock may test its immediate support if selling pressure persists, yet the infusion of capital could act as a stabilising Factor should market sentiment improve. Investors should therefore monitor price action around the identified support and resistance thresholds, as any breach could signal a shift in market perception of the merger’s feasibility.

Next Milestone: Merger Closure

The merger with Eos Senolytix is slated for completion in the third quarter of 2026, pending customary closing conditions. Upon consummation, the combined entity will inherit Eos’s gerotherapeutic pipeline, augmenting Pulmatrix’s product suite and potentially unlocking new Revenue streams. The forthcoming merger serves as a key catalyst, with the actual closing date expected to crystallise in the coming weeks.

Success will transform the company’s balance sheet, potentially converting the restricted cash into unrestricted liquidity and enhancing Shareholder value through combined assets. Conversely, any delay or failure could strain the limited cash reserves and exacerbate existing losses. Market Participants will thus watch regulatory filings and merger‑related disclosures closely as the quarter progresses.

Peers Moving on This News